Synthesis and Evaluation of Linear and Macrocyclic Dolastatin 10 Analogues Containing Pyrrolidine Ring Modifications

被引:16
作者
Akaiwa, Michinori [1 ,2 ]
Martin, Tioga [1 ,3 ]
Mendelsohn, Brian A. [1 ,4 ]
机构
[1] Agensys Inc, 1800 Stewart St, Santa Monica, CA 90404 USA
[2] Astellas Pharma, Tsukuba Res Ctr, 21 Miyukigaoka, Tsukuba, Ibaraki 3058585, Japan
[3] Asilomar Bio Inc, 5858 Horton St, Emeryville, CA 94608 USA
[4] Ajinomoto Althea Inc, 11040 Roselle St,San, San Diego, CA 92121 USA
关键词
ADVANCED SOLID TUMORS; PHASE-II TRIAL; STRUCTURAL MODIFICATIONS; ANTINEOPLASTIC AGENTS; ANTITUMOR-ACTIVITY; CELL-DEATH; CANCER; TZT-1027; CHEMOTHERAPY; DISCOVERY;
D O I
10.1021/acsomega.8b00093
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Because of their potent cytotoxic activity, members of the auristatin family (synthetic analogues of the naturally occurring dolastatin 10) have remained a target of significant research, most notably in the context of antibody drug conjugate payloads. Typically, modifications of the backbone scaffold of dolastatin 10 have focused on variations of the N-terminal (P1) and C-terminal (P5) subunits. Scant attention has been paid thus far to the P4 subunit in the scientific literature. In this paper, we introduce an azide functional group at the P4 subunit, resulting in potent cytotoxic activity seen in vitro. Another highly active compound in this study contained azide functional groups in both the P2 and P4 subunits and required dolavaline as the P1 subunit and a phenylalanine as the P5 subunit. Furthermore, these two azide groups served not only as modifiers of cytotoxicity but also as handles for linker attachment or as a tether for use in the synthesis of a macrocyclic analogue.
引用
收藏
页码:5212 / 5221
页数:10
相关论文
共 37 条
[1]  
Chakraborty T. K., 2012, PCT Appl., Patent No. [WO 2012123957, 2012123957]
[2]   Antibody- Drug Conjugates: An Emerging Concept in Cancer Therapy [J].
Chari, Ravi V. J. ;
Miller, Michael L. ;
Widdison, Wayne C. .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2014, 53 (15) :3796-3827
[3]   Application of Organic Azides for the Synthesis of Nitrogen-Containing Molecules [J].
Chiba, Shunsuke .
SYNLETT, 2012, 23 (01) :21-44
[4]   A tale of two tumor targets: Topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy [J].
Cragg, GM ;
Newman, DJ .
JOURNAL OF NATURAL PRODUCTS, 2004, 67 (02) :232-244
[5]   Impact of Natural Products on Developing New Anti-Cancer Agents [J].
Cragg, Gordon M. ;
Grothaus, Paul G. ;
Newman, David J. .
CHEMICAL REVIEWS, 2009, 109 (07) :3012-3043
[6]   Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors [J].
de Jonge, MJA ;
van der Gaast, A ;
Planting, AST ;
van Doorn, L ;
Boot, ALI ;
Wanders, J ;
Satomi, M ;
Verweij, J .
CLINICAL CANCER RESEARCH, 2005, 11 (10) :3806-3813
[7]   Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity [J].
Doronina, SO ;
Mendelsohn, BA ;
Bovee, TD ;
Cerveny, CG ;
Alley, SC ;
Meyer, DL ;
Oflazoglu, E ;
Toki, BE ;
Sanderson, RJ ;
Zabinski, RF ;
Wahl, AF ;
Senter, PD .
BIOCONJUGATE CHEMISTRY, 2006, 17 (01) :114-124
[8]   Synthesis and Evaluation of Dolastatin 10 Analogues Containing Heteroatoms on the Amino Acid Side Chains [J].
Dugal-Tessier, Julien ;
Barnscher, Stuart D. ;
Kanai, Akira ;
Mendelsohn, Brian A. .
JOURNAL OF NATURAL PRODUCTS, 2017, 80 (09) :2484-2491
[9]   Microtubule-binding agents: a dynamic field of cancer therapeutics [J].
Dumontet, Charles ;
Jordan, Mary Ann .
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (10) :790-803
[10]  
Flahive E, 2012, ANTICANCER AGENTS FROM NATURAL PRODUCTS, 2ND EDITION, P263